Xuan Wang1, Meihong Xiu2, Keqiang Wang1, Xiuru Su1, Xirong Li2, Fengchun Wu3,4,5. 1. Hebei Province Veterans Hospital, Baoding, China. 2. Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, China. 3. Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Liwan District, Guangzhou, 510370, China. 13580380071@163.com. 4. Department of Biomedical Engineering, Guangzhou Medical University, Liwan District, Guangzhou, 510370, China. 13580380071@163.com. 5. Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Liwan District, Guangzhou, 510370, China. 13580380071@163.com.
Abstract
INTRODUCTION: Olanzapine (OLA) is one of the most commonly used second-generation antipsychotics for the treatment of schizophrenia. However, the heterogeneity of therapeutic response to OLA among schizophrenia patients deserves further exploration. The role of carnitine in the clinical response to OLA monotherapy remains unclear. OBJECTIVES: The current study was designed to investigate whether carnitine and its derivatives are linked to the response to OLA treatment. Drug-naïve first-episode patients with schizophrenia were recruited and treated with OLA for 4 weeks. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) in pre and post treatment. RESULTS: After treatment, we found a significant decrease in 2-Octenoylcarnitine levels and a significant increase in linoelaidyl carnitine, 11Z-Octadecenylcarnitine and 9-Decenoylcarnitine levels. Furthermore, baseline linoelaidyl carnitine levels were correlated with the reduction of PANSS positive symptom subscore. Linear regression and logistic regression analyses found that the baseline linoelaidyl carnitine level was a predictive marker for the therapeutic response to OLA monotherapy for 4 weeks. CONCLUSION: Our pilot study suggests that linoelaidyl carnitine levels at baseline may have a predictive role for the improvement of positive symptoms after OLA monotherapy in the patients with schizophrenia.
INTRODUCTION: Olanzapine (OLA) is one of the most commonly used second-generation antipsychotics for the treatment of schizophrenia. However, the heterogeneity of therapeutic response to OLA among schizophrenia patients deserves further exploration. The role of carnitine in the clinical response to OLA monotherapy remains unclear. OBJECTIVES: The current study was designed to investigate whether carnitine and its derivatives are linked to the response to OLA treatment. Drug-naïve first-episode patients with schizophrenia were recruited and treated with OLA for 4 weeks. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) in pre and post treatment. RESULTS: After treatment, we found a significant decrease in 2-Octenoylcarnitine levels and a significant increase in linoelaidyl carnitine, 11Z-Octadecenylcarnitine and 9-Decenoylcarnitine levels. Furthermore, baseline linoelaidyl carnitine levels were correlated with the reduction of PANSS positive symptom subscore. Linear regression and logistic regression analyses found that the baseline linoelaidyl carnitine level was a predictive marker for the therapeutic response to OLA monotherapy for 4 weeks. CONCLUSION: Our pilot study suggests that linoelaidyl carnitine levels at baseline may have a predictive role for the improvement of positive symptoms after OLA monotherapy in the patients with schizophrenia.
Authors: Fabiano R Agostinho; Gislaine Z Réus; Roberto B Stringari; Karine F Ribeiro; Gabriela K Ferreira; Isabela C Jeremias; Giselli Scaini; Gislaine T Rezin; Emílio L Streck; João Quevedo Journal: Acta Neuropsychiatr Date: 2011-12 Impact factor: 3.403
Authors: Céline Aguer; Colin S McCoin; Trina A Knotts; A Brianne Thrush; Kikumi Ono-Moore; Ruth McPherson; Robert Dent; Daniel H Hwang; Sean H Adams; Mary-Ellen Harper Journal: FASEB J Date: 2014-10-23 Impact factor: 5.191
Authors: Michael L Blackburn; Kikumi Ono-Moore; Hany F Sobhi; Sean H Adams Journal: Am J Physiol Endocrinol Metab Date: 2020-05-27 Impact factor: 4.310
Authors: Vance L Albaugh; Thomas C Vary; Olga Ilkayeva; Brett R Wenner; Kevin P Maresca; John L Joyal; Steven Breazeale; Tedd D Elich; Charles H Lang; Christopher J Lynch Journal: Schizophr Bull Date: 2010-05-21 Impact factor: 9.306
Authors: Catia Testa Cavedon; Pierre Bourdoux; Karl Mertens; Hong Vien Van Thi; Nadine Herremans; Corinne de Laet; Philippe Goyens Journal: Clin Chem Date: 2005-02-11 Impact factor: 8.327
Authors: Elvira Bramon; Emma Dempster; Sophia Frangou; Madiha Shaikh; Muriel Walshe; Francesca M Filbey; Colm McDonald; Pak Sham; David A Collier; Robin Murray Journal: Schizophr Res Date: 2008-06-20 Impact factor: 4.939